TP-271

TP-271 is a novel, fully synthetic fluorocycline antibiotic developed for the treatment of respiratory infections, including community-acquired bacterial pneumonia and other complicated bacterial respiratory infections. It acts as a broad-spectrum antibacterial agent by inhibiting the protein synthesis of bacteria through binding to the 30S ribosomal subunit. Unlike traditional tetracyclines, TP-271 retains activity against strains expressing common tetracycline resistance mechanisms such as efflux pumps and ribosomal protection proteins (including Tet(M)), as well as Tet(X) inactivating enzymes[2][5][6][8]. The drug demonstrated potent in vitro activity against both Gram-positive and Gram-negative pathogens associated with respiratory tract infections, including multidrug-resistant organisms[5][7]. Developed originally by Tetraphase Pharmaceuticals with support from the NIH’s National Institute of Allergy and Infectious Diseases (NIAID), it received FDA Qualified Infectious Disease Product (QIDP) and Fast Track designations for its intravenous formulation[7]. Clinical development reached Phase 1 trials but was discontinued for all indications[2].

Other names

TP 271TP271TP-271